Regeneron Will Move Two Factor XI Agents Into Phase III

With successful Phase II data versus active comparators for both REGN7508 and REGN9933, Regeneron hopes to position the candidates to compete against existing factor X products.

Regeneron reports positive Phase II data for two factor XI anticoagulants • Source: Shutterstock

More from Strategy

More from Therapy Areas